Status:
RECRUITING
RESistance of IgA Nephropathy to Conventional and Newly-approved Therapies: an Observational, Real-life Study (RESIGAN)
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
IgA Nephropathy (IgAN)
Eligibility:
All Genders
18+ years
Brief Summary
IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide, characterized by glomerular mesangial IgA deposits, often with IgG and C3. Despite its prevalence, the pathophysiology o...
Detailed Description
IgA Nephropathy (IgAN) is the most prevalent primary glomerulonephritis globally, diagnosed by detecting mesangial IgA deposits in the kidneys, often accompanied by IgG and C3. The disease's pathophys...
Eligibility Criteria
Inclusion
- Adult patient: age ≥ 18 years
- Renal biopsy performed after 2017 showing IgA deposits leading to the diagnosis of IgAN (the date of diagnosis being the index date)
- Informed patient and who does not object to the use of his data
Exclusion
- \- None
Key Trial Info
Start Date :
June 23 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2029
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT06926244
Start Date
June 23 2025
End Date
April 1 2029
Last Update
July 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nephrology department, Hospital Pitié - Salpêtrière (ASSISTANCE PUBLIQUE HOPITAUX DE PARIS AP-HP)
Paris, France, 75013